Trastuzumab biosimilar - Celltrion

Drug Profile

Trastuzumab biosimilar - Celltrion

Alternative Names: CT-P06; CT-P6; Herzuma

Latest Information Update: 11 Oct 2016

Price : $50

At a glance

  • Originator Celltrion
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer; Gastric cancer

Most Recent Events

  • 06 Oct 2016 Trastuzumab biosimilar licensed to Teva Pharmaceutical Industries in USA and Canada
  • 06 Oct 2016 Celltrion announces intention to submit MAA with EMA in Q4 2016
  • 01 Apr 2016 Celltrion completes a phase I clinical trial in Breast cancer (In volunteers) in USA (IV) (NCT02665637)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top